Booth: 601, 821, 606
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
Alfa Wassermann clinical chemistry systems use liquid, ready-to-use reagents, providing an inexpensive alternative to dry chemistry. Alfa Wassermann offers a compact, cost-effective, easy-to-use, innovative benchtop blood chemistry analyzer to maximize research success by quickly and cost effectively transforming in-vivo drug safety and efficacy screens.
Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.
Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, and hepatic infectious diseases with unmet need. Alnylam’s investigational medicines include four late-stage product candidates, with one under regulatory review. www.alnylam.com.
The Alpha-1 Foundation is a not-for-profit organization that is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency.
Founded in 1976, the American Liver Foundation (ALF) is the nation’s leading nonprofit health organization for people living with liver disease. We are a nationwide network of staff and volunteers that provides awareness, outreach, education and patient support services to educate the public about liver health and to improve the lives of individuals and their families affected by liver disease.
The mission of the American Porphyria Foundation is to enhance awareness and education about the Porphyrias and to aid in advancing treatment of this group of disorders.
Today APASL is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.
A non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and the exchange of scientific knowledge and experiences, to reduce current gaps in the world.
The Mexican Hepatology Association is a leading organization involved in the advancement of science and practice of hepatology, promoting better care for patients with liver and biliary diseases. It is involved in the innovation and development of new therapeutic options and is committed to the training of specialists.
Baxter renal products help make renal care options more accessible to the individual. We provide a full range of dialysis and therapy options for patient-specific care, including in-center hemodialysis, peritoneal dialysis and continuous renal replacement therapy, backed by industry-leading services for patients and clinicians.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.
BioPredictive is benchmark in blood tests for liver diseases. BioPredictive is dedicated to improve the management of liver diseases. Over 2,5 million tests performed worldwide. BioPredictive’s diagnosis and prognosis patented tests (FiboTest-ActiTest, SteatoTest, and just released in 2019 the NASH-Fibro Test) are available at www.biopredictive.com
Blue Faery: The Adrienne Wilson Liver Cancer Association is devoted to fighting primary liver cancer. Founded in Burbank, California, with a satellite location in Birmingham, Alabama, Blue Faery’s mission is to prevent, treat and cure primary liver cancer through research, education and advocacy. For more information, visit www.bluefaery.org.
BriovaRx is a leading specialty pharmacy services company dedicated to helping administer and deliver high-quality, cost-effective specialty pharmacy care. BriovaRx combines technology, data and expertise to provide educational resources, 24/7 pharmacy support and trusted advice to the individuals, caregivers and care teams we serve.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Visit BMS at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer.
The Chronic Liver Disease Foundation (CLDF) is an educational organization dedicated to increasing the awareness of the effects of chronic liver disease in the United States. The CLDF's goal is to provide healthcare professionals with the most current education and information on chronic liver disease.
The Cochrane Hepato-Biliary Group (CHBG), part of Cochrane, is a non-profit, non-industry funded international clinical research group with 2300 members. In issue 4, 2018 of The Cochrane Library, we published 343 peer-reviewed protocols and 211 systematic reviews. A CHBG Register with RCTs and CCTs is maintained in The Cochrane Library.
The Community Liver Alliance connects patients to health care providers and services; creates and conducts screenings and educational programs; supports local youth transplant camp; promotes awareness of liver wellness; offers a patient assistance program, funds local research and meets with local, state, and federal policy makers to initiate positive change.
CTI is a global, privately held, full-service CRO with a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. We specialize in the unique challenges associated with hepatic populations, and our therapeutic expertise is a driving force enabling us to successfully design/manage drug development programs in hepatology.
Our commitment to helping patients and their physicians manage complex drug therapies by delivering expert individualized care and unmatched, multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing the latest FDA-approved medications.
See what’s new in liver injury biomarkers for NASH, AH, and DILI research at Booth 601. Cytokeratin/Keratin 18 (CK18/K18) is an important biomarker of hepatocyte cell death. Explore RUO M30/M65 ELISAs for measuring hepatocyte apoptosis/necrosis non-invasively. Diapharma offers additional RUO assays for liver injury, including HA, α-GST, and Collagen IV.
Founded on innovation and committed to consumer education, Diem Labs, LLC delivers clinically validated nutritional products that address underserved and unmet medical needs. Hepaxa™ is a first-in-class medical food product consisting of a patented, concentrated and purified EPA/DHA complex, indicated for the management of steatosis in non-alcoholic fatty liver disease (NAFLD).
Visit us to learn about liver programming at Digestive Disease Week® (DDW) 2019. Then get ready to commemorate 50 years of DDW in San Diego, CA, May 18-21, 2019. The global destination for GI education, DDW is the leading meeting to update clinical knowledge, share research, and make and renew connections with peers.
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.
Dynavax is a commercial-stage biopharmaceutical company. Our FDA-approved Hepatitis B vaccine is the only two-dose hepatitis vaccine for adults that completes the series in 1 month. It is the first approved hepatitis B vaccine in over 25 years and received a unanimous recommendation from the Advisory Committee on Immunization Practice.
Echosens™ is the world's leading provider of non-invasive liver medical devices. FibroScan® systems are FDA cleared as an aid for the diagnosis and monitoring of liver disease. FibroScan® is supported by over 3,000 peer reviewed publications and is the reference for many of the leading treatment guidelines in liver disease.
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of commercial focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
ALEH is a Non-profit scientific association, whose main objective is to promote and disseminate the study of Hepatology in Latin America. ALEH seeks to establish solid leadership within the field at a global level via diverse activities: Training and the exchange of scientific knowledge to reduce gaps in the region.
ENDRA Life Sciences (NASDAQ: NDRA) is a development stage company with a breakthrough Thermo-Acoustic Enhanced UltraSound (TAEUS) enabling clinicians to visualize human tissue composition, function and temperature. Initial application is quantification of fat in the liver, for early detection and monitoring of NAFLD, which affects over 1 billion people globally.
Since 1966, EASL has continued to grow into a major European Association with international influence dedicated to liver research. It has over 4,400 members and its International Liver Congress™ unites over 10,000 liver experts. EASL supports clinical trials and research to the benefit of patients world-wide.
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Exelixis is on a mission to help patients recover stronger and live longer.
Early detection of HCC is crucial for the application of curative therapies. Adding HCC risk biomarkers, AFP-L3 (lectin-reactive alpha-fetoprotein) and DCP (des-gamma-carboxy prothrombin, PIVKA-II) to your HCC surveillance practice can increase chances of detecting HCC earlier. Both tests are 510(k)-cleared, CMS-reimbursed, and available at major US reference laboratories.
Gastroenterology & Endoscopy News, a monthly newspaper, provides smart, objective and comprehensive clinical news reporting from international, national and regional gastroenterology meetings. It also features in-depth original articles, educational reviews, CME monographs and monthly commentary from celebrated gastroenterologists.
Gastroenterology & Hepatology is a monthly, independent peer-reviewed journal that is mailed to all US gastroenterologists and hepatologists (16,700+). Content is directed by strong input of experts in the field. G&H contains thought leader-driven review articles, clinical case studies with expert commentary, and advances columns featuring engaging interviews with experts on current issues in IBD, IBS, GERD, Hepatitis and Endoscopy.
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases, where there is still considerable unmet need. Elafibranor, its lead compound, is currently evaluated in a Phase 3 study in NASH.
Booth: 801, 1013, 1005, 813
Gilead Sciences, Inc., founded in 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead's portfolio includes treatments for HIV/AIDS, hepatitis, respiratory and cardiovascular conditions, cancer and inflammation. Gilead is one of the world’s largest biopharmaceutical companies, with approximately 5,500 employees across four continents.
GSK Oncology is dedicated to pursuing innovation in cancer care to make a difference for patients, physicians and communities. At GSK Oncology, what defines us is our pledge to engage and work with our communities as we strive to bring forth meaningful treatment choices.
Gore Medical Products Division engineers devices that treat a range of cardiovascular, bariatric, hernia and other health conditions. Gore builds on its legacy of improving patient outcomes through research, education, and quality initiatives. Product performance, ease of use, and quality of service provide sustainable clinical and economic value for physicians, hospitals, and insurers.
We’re reporting LIVE. Follow what’s trending at Healio.com/GI. See what your peers are reading online – in print. Stop by our booth and pick up your free issue of Healio Gastroenterology – a unique peer-tested news magazine. Also see HCV Next. Go to Healio.com/Register.
The HealthWell Foundation is an independent non-profit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can't afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org.
IIAM is a world-leading provider of non-transplantable, healthy and diseased, human organs and tissues for medical research, education and development. These tissues are recovered with minimal ischemia, stored in preservation and delivered in 12-24 hours to qualified researchers, scientists, healthcare and biotech professionals for medical advancement. Visit our website, www.iiam.org.
INDIGO Biosciences, Inc. has established itself as the industry-leading provider of assay kits and screening services focused on nuclear receptors. With the world’s largest portfolio, INDIGO products and services help customers improve the speed to data, accuracy, ease of use, and cost efficiency of their drug discovery research.
Booth: 317, 921
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
Covance is the world’s most comprehensive drug development company. LabCorp, our parent company, is a market leader in diagnostics with strength in the management of infectious diseases. Together, we offer a single-source solution for drug development and treatment of acute and chronic infections. Together, we improve health and improve lives.
Mayo Medical Laboratories (MML) is a global reference laboratory bringing Mayo Clinic diagnostic excellence to physicians and patients around the world. MML performs 24 million reference laboratory tests annually and offers 24-hours access to diagnostic and clinical consultation.
Medical Solutions is an official distributor of LED medical devices.
MYR Pharmaceuticals is focused on the development of bulevirtide, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. MYR started its operations in 2011. Its technology was originally developed at the University of Heidelberg, INSERM and now represents one the most clinically advanced novel approaches for treatment of hepatitis B/D.
Novartis, a leading global medicines company, is reimagining medicine to improve and extend people’s lives through innovation and digital technologies to create transformative treatments in areas of great medical need. Novartis reaches more than 750 million people and we are finding innovative ways to expand access to our latest treatments.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders, obesity, chronic kidney disease, cardiovascular disease and NASH .
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
Our mission is to unite people diagnosed with Primary Biliary Cholangitis (formerly known as Primary Biliary Cirrhosis), which is a progressive chronic liver disease. Our organization helps PBC patients, their care givers, friends and families cope with PBC and improve the quality of their lives through education and support.
Perspectum Diagnostics provides digital health solutions for metabolic disease. LiverMultiScan, uses multiparametric MRI to provide quantitative analysis of liver tissue, measuring fat, correlates of iron and fibroinflammatory disease. MRCP+ allows 3D visualisation and quantitative mapping of the pancreatobiliary system and will be showcased on the booth.
PhoenixBio produces the PXB-Mouse®, the world’s most widely used humanized liver chimeric mouse model, for pre-clinical development. With a liver consisting up to 95% human hepatocytes, the PXB-Mouse® offers reproducible human translatability in the fields of DMPK/Tox, HBV/HCV, NASH/NAFLD and Gene Editing/Oligonucleotide Therapeutics, saving time and costs in pre-clinical development.
Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases by developing cell and antibody technologies. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties.
Prometheus is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. We are primarily focused on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology.
ProSciento is a specialty CRO exclusively focused on NASH, diabetes and obesity. ProSciento provides comprehensive and customized services for multinational, early development clinical trial programs for biopharma companies worldwide. Founded in 2003, ProSciento has completed over 280 clinical projects and contributed to more than 15 approved metabolic drugs and devices.
PSC Partners Seeking a Cure provides education and support to PSC patients, families and caregivers, and raises funds to research causes, treatments and cures for Primary Sclerosing Cholangitis. PSC Partners has awarded $3 million in research grants, has a growing patient registry, and holds annual conferences for patients and caregivers.
Research Diets, Inc. formulates and produces purified OpenSource Diets® for laboratory animals. Custom diets shipped in 5-7 days. BioDAQ® Food and Liquid Intake Monitor for mice and rats mounts to home cage and records the time, duration, amount of each meal automatically. BioDAQ NHP monitors food intake of socially housed NHPs.
Resoundant, Inc. produces magnetic resonance elastrography, MRE, technology that is available for new and existing MRI scanners manufactured by Philips, GE and Siemens. MRE was developed by Dr. Richard Ehman and his team at the Mayo Clinic. There are nearly 900 systems installed around the world. www.resoundant.com
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
For almost 30 years, Salix Pharmaceuticals has been committed to the prevention and treatment of gastrointestinal diseases. Salix licenses, develops, and markets innovative products to improve patients’ lives and arm healthcare providers with lifechanging solutions. Salix is headquartered in Bridgewater, New Jersey.
Sanyal Biotechnology is a full-service contract research organization specializing in pre-clinical small animal model screening of drugs. Our flagship DIAMOND™ mouse develops full metabolic syndrome solely as a result of Western Diet. We have the capability to screen drugs throughout the development timeline from basic toxicology to efficacy.
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a drug discovery-based pharmaceutical company founded in Osaka, Japan 139 years ago. Our focus is on developing the best possible medicines that address unmet medical needs and help patients and their families worldwide.
SuperSonic Imagine develops and markets a non- invasive liver assessment tool, Aixplorer®, that provides a solution for the assessment and monitoring of chronic liver disease. Real-time ShearWave™ Elastography (SWE™) delivers liver stiffness measurements under ultrasound guidance, and has been validated in over 150 peer-reviewed publications.
Since the program's inception in 1981, UPMC Transplant Services has been a pioneer in the development and refinement of new transplant procedures. UPMC is committed to reducing waiting list deaths through robust living-donor kidney and living-donor liver transplant programs, as well as other innovative methods to expand the donor pool.
Virology Education is a leading provider of innovative scientific and educational programs worldwide, with over 20 years of experience and a wide network of experts. Our programs provide platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of virology and liver disease.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments, and individuals increase the academic and professional impact of their work.
The World Gastroenterology Organisation (WGO) is a federation comprised of over 110 gastroenterology, hepatology, endoscopy, and other related-discipline societies representing more than 50,000 individuals worldwide. WGO focuses on the improvement of standards in gastroenterology training and education globally. The WGO Foundation is the philanthropic resource for the WGO mission.
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.